ARGX
$663.93-20.57 (-3.01%)
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Recent News
Argenx Data At AAN Puts VYVGART Neuromuscular Upside In Focus
argenx (ENXTBR:ARGX) plans to present new Phase 3 data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting. The data include results in ocular myasthenia gravis, seronegative generalized myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Real world evidence and biomarker findings are also set to be shared, highlighting clinical experience with VYVGART. For investors tracking neurology focused drug developers, argenx is drawing...
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating. The company reported earnings per share of $8.02, exceeding the projected $5.95. […]
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’
Investing.com -- Deutsche Bank upgraded Argenx (EBR:ARGX) to Buy from Hold and raised its price target to €725, citing a more attractive valuation and continued commercial momentum for its key product Vyvgart despite a mixed fourth-quarter update.
Assessing Argenx (ENXTBR:ARGX) Valuation After First-Year Profitability And Positive VYVGART Phase 3 Results
argenx (ENXTBR:ARGX) has drawn fresh investor interest after reporting its first year of operating profitability and releasing positive Phase 3 VYVGART data in ocular myasthenia gravis, alongside plans for broader MG indications. See our latest analysis for argenx. Despite the strong news flow around first year profitability and positive VYVGART data, argenx’s recent share price performance has cooled. The 30 day share price return is 9.34%, while the 90 day share price return reflects a...